title: Contribution of CA3 and CA1 pyramidal neurons to the tonic α7 nAChR-dependent glutamatergic input to CA1 pyramidal neurons.
abstract: The Schaffer collaterals are among the major glutamatergic inputs to CA1 pyramidal neurons, the primary output of the hippocampus, which also receive sparse recurrent inputs from pyramidal neurons in the CA1 field. Although tonically active α7 nicotinic acetylcholine receptors (nAChRs) have been shown to sustain spontaneous glutamate transmission to CA1 pyramidal neurons in hippocampal slices under resting conditions, it remains to be determined whether these receptors are those expressed by CA3 or CA1 pyramidal neurons. This study was designed to test the hypothesis that the CA3 field of the hippocampus is a significant source of α7 nAChR-sustained glutamatergic transmission to CA1 pyramidal neurons. To this end, spontaneous excitatory postsynaptic currents (EPSCs) were recorded from CA1 and CA3 pyramidal neurons in intact rat hippocampal slices as well as from CA1 pyramidal neurons in CA3-ablated slices under various experimental conditions. Surgical removal of the CA3 region from the slices reduced by 20% the frequency of spontaneous EPSCs recorded from CA1 pyramidal neurons. This finding is in agreement with the concept that the CA3 field contributes significantly to the maintenance of spontaneous glutamatergic synaptic activity in CA1 pyramidal neurons. In addition, the α7 nAChR antagonist methyllycaconitine (MLA, 10nM) reduced the frequency of spontaneous EPSCs recorded from CA1 pyramidal neurons by 30% in intact slices and 12% in CA3-ablated slices. Taken together, these results demonstrate that tonically active α7 nAChRs in CA3 pyramidal neurons and/or in the Mossy fibers that innervate the CA3 pyramidal neurons do in fact contribute to the maintenance of glutamatergic synaptic activity in CA1 pyramidal neurons of hippocampal slices under resting conditions.
authors: Division of Translational Toxicology, Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, MD, United States. Electronic address: banerjee@umaryland.edu.
authors: Jyotirmoy
authors: J
authors: Banerjee
authors: Manickavasagom
authors: M
authors: Alkondon
authors: Edson X
authors: EX
authors: Albuquerque
authors: Edna F R
authors: EF
authors: Pereira
mesh_terms: D000157:Aconitine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D056547:CA1 Region, Hippocampal / Q000166:cytology / Q000378:metabolism*; D056654:CA3 Region, Hippocampal / Q000166:cytology / Q000378:metabolism*; D019706:Excitatory Postsynaptic Potentials; D018698:Glutamic Acid / Q000378:metabolism*; D066298:In Vitro Techniques; D053444:Inhibitory Postsynaptic Potentials; D008297:Male; D017966:Pyramidal Cells / Q000378:metabolism*; D017207:Rats, Sprague-Dawley; D026941:Sodium Channel Blockers / Q000494:pharmacology; D009435:Synaptic Transmission; D013779:Tetrodotoxin / Q000494:pharmacology; D064569:alpha7 Nicotinic Acetylcholine Receptor / Q000037:antagonists & inhibitors / Q000378:metabolism*
chemical_list: D026941:Sodium Channel Blockers; D064569:alpha7 Nicotinic Acetylcholine Receptor; C054634:methyllycaconitine; D018698:Glutamic Acid; D013779:Tetrodotoxin; D000157:Aconitine
keywords: 2-amino-5-phosphonovaleric acid; 6-cyano-7-nitroquinoxaline-2,3-dione; ACSF; APV; CNQX; EPSC; Hippocampus; IPSC; MLA; Methyllycaconitine; Pyramidal neuron; TTX; Tetrodotoxin; artificial cerebrospinal fluid; excitatory postsynaptic current; inhibitory postsynaptic current; methyllycaconitine; nAChR; nicotinic acetylcholine receptor; tetrodotoxin; time constant of decay; α7 nAChR; τ(d)
references: Physiol Rev. 2009 Jan;89(1):73-120
references: 19126755
references: J Mol Neurosci. 2010 Jan;40(1-2):114-20
references: 19693709
references: Br J Pharmacol. 2010 Feb 1;159(3):554-65
references: 20105181
references: Nat Neurosci. 2004 Feb;7(2):126-35
references: 14730307
references: Eur J Neurosci. 2011 May;33(10):1786-98
references: 21501254
references: Neuron. 2001 Jul 19;31(1):131-41
references: 11498056
references: Nature. 1996 Oct 24;383(6602):713-6
references: 8878480
references: J Physiol. 1999 Mar 15;515 ( Pt 3):769-76
references: 10066903
references: J Physiol. 2005 Jan 1;562(Pt 1):9-26
references: 15539390
references: J Neurosci. 2008 Mar 5;28(10):2563-75
references: 18322100
references: J Pharmacol Exp Ther. 2011 Jun;337(3):572-82
references: 21270133
references: J Physiol. 1986 Apr;373:397-418
references: 3018233
references: Neuroscience. 1996 Oct;74(4):1009-18
references: 8895869
references: Physiol Rev. 2011 Apr;91(2):555-602
references: 21527732
references: Nature. 1990 Aug 23;346(6286):724-9
references: 2167454
references: J Pharmacol Exp Ther. 2012 May;341(2):500-9
references: 22344459
references: J Neurosci. 1990 Mar;10(3):826-36
references: 2319304
references: Biochem Pharmacol. 2012 Oct 15;84(8):1078-87
references: 22889930